


-124-

Claims:

1. A novel benzofuran derivative of the formula



wherein

R^1 and R^2 represent, independently, a hydrogen atom or a C_{1-4} alkyl group,

X stands for an oxygen atom or a sulfur atom,

Y means a hydrogen atom or a hydroxy group,

Z represents a hydrogen atom, a halo atom,

a C_{1-4} alkyl group, a C_{1-4} alkoxy group,

an amino group, a nitro group, a cyano group,

a trifluoromethyl group, a group of the formula $-COOR^3$, $-NHCOR^3$ or

$-SO_2NR^3R^4$, wherein

R^3 stands for a hydrogen atom or a C_{1-4} alkyl group,

R^4 is a C_{1-4} alkyl group, or

R^3 and R^4 form, together with the adjacent nitrogen atom, a saturated or unsaturated heterocyclic group having 5 to 10 members and optionally comprising one or more nitrogen atom(s) and/or one or more oxygen atom(s) and/or one or more sulfur atom(s) as the further heteroatom(s),

A means a group of the formula CH , COH , $C-CN$, $C-COOR^3$ or COR^4 , wherein R^3 and R^4 are

-125-

as defined above,
B represents a methylene group, or
A forms together with B a group of the formula
-C=C-,
Ar stands for a hydrogen atom, a C₁₋₄ alkyl
group, a phenyl(C₁₋₄ alkyl) group, a
biphenylyl group, a naphthyl group, wherein
said latter species are optionally
substituted by a C₁₋₄ alkoxy group or
a C₂₋₄ alkenyl group; a partially saturated,
5- or 6-membered heterocyclic group
condensed with a phenyl group and containing
one or two oxygen atom(s), said heterocyclic
group being optionally substituted by one
to three C₁₋₄ alkyl group; a 5- or
6-membered, saturated or unsaturated hetero
cyclic group containing a nitrogen atom
and/or an oxygen atom and/or a sulfur atom
as the heteroatom; or a phenyl group
substituted by the substituents R⁵, R⁶
and R⁷, wherein
R⁵, R⁶ and R⁷ mean, independently, a
hydrogen atom, a halo atom, a trifluoro-
methyl group, a C₁₋₄ alkyl group, a
methylenedioxy group, a phenoxy group
optionally substituted by a C₁₋₄ alkoxy
group or by a halo atom; a C₂₋₄ alkenyl
group, a C₂₋₄ alkenyloxy group, a C₁₋₄
alkoxy group optionally substituted
by a di(C₁₋₄ alkyl)amino group or by
a 5- or 6-membered, saturated hetero-
cyclic group containing one or two

-126-

nitrogen atom(s) or a nitrogen atom and an oxygen atom, wherein said heterocyclic group is optionally substituted by a C_{1-4} alkyl group, or A stands for a group of the formula $N-(CH_2)_n-Ar'$, wherein Ar' represents a diphenylmethyl group, a pyridyl group, a pyrimidinyl group, a naphthyl group, wherein said latter group is optionally substituted by a C_{1-4} alkoxy group or a C_{2-4} alkenyloxy group; a partially saturated, 5- or 6-membered heterocyclic group condensed with a phenyl group and containing one or two oxygen atom(s), said heterocyclic group being optionally substituted by one to three C_{1-4} alkyl group(s); or a phenyl group substituted by the substituents R^5 , R^6 and R^7 , wherein R^5 , R^6 and R^7 are as defined above,
n has a value of 0 or 1,
and pharmaceutically suitable acid addition salts thereof.

2. A benzofuran derivative as claimed in Claim 1, wherein in formula I
 R^1 represents a hydrogen atom or a C_{1-4} alkyl group,
 R^2 stands for a hydrogen atom,
X means an oxygen atom,
Y is a hydrogen atom or a hydroxy group,
Z represents a hydrogen atom, a halo atom

-127-

or a nitro group,

A stands for a group of the formula CH, COH or C-CN,

B means a methylene group, or

A forms with B a group of the formula -C=C-,

Ar represents a hydrogen atom, a benzyl group, a phenyl group substituted by substituents

R^5 , R^6 and R^7 , a biphenylyl group, a

naphthyl group optionally substituted

by a C_{1-4} alkoxy group; or a thiienyl group,

wherein

R^5 , R^6 and R^7 mean, independently, a hydrogen atom, a halo atom, a trifluoromethyl group, a C_{1-4} alkyl group, a C_{1-4} alkoxy group, a C_{2-4} alkenyloxy group, a phenoxy group or a methylenedioxy group,

and pharmaceutically suitable acid addition salts thereof.

3. A benzofuran derivative as claimed

in Claim 1 or 2, wherein in formula I

R^1 represents a methyl group,

R^2 stands for a hydrogen atom,

X means an oxygen atom,

Y is a hydroxy group,

Z represents a hydrogen atom,

A is a group of the formula CH, COH or C-CN,

B stands for a methylene group, or

A forms with B a group of the formula -C=C-,


Ar represents a phenyl group optionally

substituted by a halo atom, a trifluoromethyl group, a methyl group or a methoxy

-128-

group; or a methoxynaphthyl group, and pharmaceutically suitable acid addition salts thereof.

4. A piperazinylalkylbenzofuran derivative of the formula



as claimed in Claim 1, wherein
 R^1 represents a C_{1-4} alkyl group,
 R^2 stands for a hydrogen atom,
 X means an oxygen atom,
 Y is a hydroxy group,
 Z represents a hydrogen atom,
 Ar' represents a diphenylmethyl group, a pyridyl group, a partially saturated 5-membered heterocyclic group containing two oxygen atoms and being condensed with a phenyl group, or a phenyl group substituted by substituents R^5 , R^6 and R^7 , wherein
 R^5 , R^6 and R^7 mean, independently, a hydrogen atom, a halo atom, a trifluoromethyl group, a C_{1-4} alkyl group, a C_{1-4} alkoxy group, or a methylenedioxyl group,
 n has a value of 0 or 1,
and pharmaceutically suitable acid addition salts thereof.

-129-

5. A piperazinylalkylbenzofuran derivative as claimed in Claim 4, wherein in formula

Ia

R^1 represents a methyl group,

R^2 stands for a hydrogen atom,

X means an oxygen atom,

Y is a hydroxy group,

Z represents a hydrogen atom,

Ar' represents a diphenylmethyl group, a pyridyl group, a benzo-1,3-dioxolanyl group or a phenyl group optionally substituted by one or two halo atom(s), one or two methyl group(s), a methylenedioxy group, a trifluoromethyl group or a methoxy group, n has a value of 0 or 1, and pharmaceutically suitable acid addition salts thereof.

6. 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine, 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-(3-trifluoromethylphenyl)piperidine, 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-(4-fluorophenyl)piperidine, 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-phenylpiperidine, 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-(3-chlorophenyl)piperidine,

-130-

1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(3-methoxy-phenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(4-methoxy-phenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(3-trifluoromethyl-phenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(4-methyl-phenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-cyano-4-phenyl-piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(4-chloro-phenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(6-methoxy-naphth-2-yl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(diphenylmethyl)-piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(4-fluorophenyl)-piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(3-trifluoro-methylphenyl)piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(4-methoxyphenyl)-


-131-

piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(benzo-1,3-dioxolan-5-yl)piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(4-chlorophenyl)-piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-benzylpiperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(2,4-dichlorophenyl)-piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(3-chlorophenyl)-piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(2-pyridyl)piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(2-methoxyphenyl)-piperazine or
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(3-methoxyphenyl)-piperazine,
and pharmaceutically suitable acid addition salts thereof.

7. A process for the preparation of a benzofuran derivative of the formula I, wherein R^1 , R^2 , Z , X , Y , A , B and Ar are as defined in Claim 1, or a pharmaceutically suitable acid addition salt thereof, characterized in that

a) a halide of the formula

-132-




wherein R^1 , R^2 , X , Y and Z are as defined in connection with formula I, Hal represents a halo atom, is reacted with a secondary amine of the formula



wherein A, B and Ar are as stated in connection with formula I; or

b) for the preparation of a benzofuran derivative of the formula I, wherein Y represents a hydroxy group, R^1 , R^2 , X , Z , A, B and Ar are as defined in connection with formula I, an epoxide of the formula




wherein R^1 , R^2 , Z and X are as defined above, is reacted with a secondary amine of the


-133-

formula IV, wherein A, B and Ar are as stated above; or

c) a compound of the formula




wherein R^1 , X and Z are as defined in connection with formula I, is reacted with a halo compound of the formula



wherein R^2 , Y, A, B and Ar are as stated in connection with formula I, Hal represents a halo atom;

d) for the preparation of a benzofuran derivative of the formula I, wherein R^1 , R^2 , X, Z, A, B and Ar are as defined in connection with formula I, a compound of the formula V, wherein R^1 , X and Z are as stated above, is reacted with an epoxide of the formula




-134-

wherein R^2 , A, B and Ar are as stated above;
or

e) for the preparation of a benzofuran derivative of the formula I, wherein A forms with B a group of the formula $-C=C-$, R^1 , R^2 , X, Y, Z and Ar are as defined in connection with formula I, a benzofuran derivative of the formula I, wherein A stands for a group of the formula COH , B represents a methylene group, R^1 , R^2 , X, Y, Z and Ar are as stated above, is dehydrated; or

f) for the preparation of a benzofuran derivative of the formula I, wherein A represents a group of the formula COH , B stands for a methylene group, R^1 , R^2 , X, Y, Z and Ar are as defined in connection with formula I, however, Ar is other than a hydrogen atom, a ketone of the formula



wherein R^1 , R^2 , X, Y and Z are as stated above, is reacted with an arylmagnesium halide of the formula

Hal-Mg-Ar

XVI

wherein Ar is as stated above, Hal represents

-135-

a halo atom, and the adduct formed is decomposed with water; or

g) for the preparation of a benzofuran derivative of the formula I, wherein A represents a group of the formula COH, B stands for a methylene group, R^1 , R^2 , X, Y, Z and Ar are as defined in connection with formula I, but Ar is other than a hydrogen atom, a ketone of the formula XV, wherein R^1 , R^2 , X, Y and Z are as stated above, is reacted with an aryl lithium compound of the formula

Li-Ar

XVII

wherein Ar is as stated above, and the adduct formed is decomposed with water; or

h) for the preparation of a benzofuran derivative of the formula I, wherein A represents a group of the formula CH, B stands for a methylene group, R^1 , R^2 , X, Y, Z and Ar are as defined in connection with formula I, a compound of the formula I, wherein A forms with B a group of the formula $-C=C-$, R^1 , R^2 , X, Y, Z and Ar are as stated above, is hydrogenized; or


i) for the preparation of a benzofuran derivative of the formula I, wherein A represents a group of the formula CH, B stands for a methylene group, R^1 , R^2 , X, Y, Z and Ar are as defined in connection with formula I, an epoxide of the formula III, wherein R^1 , R^2 , Z and X are as stated above, is reacted

-136-

with a secondary amine of the formula IV, wherein A stands for a group of the formula CHO_H, B and Ar are as stated above, under dehydrating reaction conditions, and the formed compound of the formula I, wherein A forms with B a group of the formula -C=C-, R¹, R², X, Y, Z and Ar are as stated above, is hydrogenized in the reaction mixture in which it was prepared; and

if desired, an obtained base of the formula I is reacted with an inorganic or organic acid to form a pharmaceutically suitable acid addition salt thereof, or liberated from the acid addition salt with a base.

8. A pharmaceutical composition comprising a benzofuran derivative of the formula



wherein

R¹ and R² represent, independently, a hydrogen atom or a C₁₋₄ alkyl group,
 X stands for an oxygen atom or a sulfur atom,
 Y means a hydrogen atom or a hydroxy group,
 Z represents a hydrogen atom, a halo atom, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, an amino group, a nitro group, a cyano

-137-

group, a trifluoromethyl group, a group of the formula $-COOR^3$, $-NHCOR^3$ or $-SO_2NR^3R^4$, wherein R^3 stands for a hydrogen atom or a C_{1-4} alkyl group, R^4 is a C_{1-4} alkyl group, or R^3 and R^4 form, together with the adjacent nitrogen atom, a saturated or unsaturated heterocyclic group having 5 to 10 members and optionally comprising one or more nitrogen atom(s) and/or one or more oxygen atom(s) and/or one or more sulfur atom(s) as the further heteroatom(s), A means a group of the formula CH , COH , $C-CN$, $C-COOR^3$ or COR^4 , wherein R^3 and R^4 are as defined above, B represents a methylene group, or A forms together with B a group of the formula $-C=C-$, Ar stands for a hydrogen atom, a C_{1-4} alkyl group, a phenyl(C_{1-4} alkyl) group, a biphenylyl group, a naphthyl group, wherein said latter species are optionally substituted by a C_{1-4} alkoxy group or a C_{2-4} alkenyl group; a partially saturated, 5- or 6-membered heterocyclic group condensed with a phenyl group and containing one or two oxygen atom(s), said heterocyclic group being optionally substituted by one to three C_{1-4} alkyl group; a 5- or 6-membered, saturated or unsaturated heterocyclic group containing a nitrogen atom

-138-

and/or an oxygen atom and/or a sulfur atom as the heteroatom; or a phenyl group substituted by the substituents R⁵, R⁶ and R⁷, wherein

R⁵, R⁶ and R⁷ mean, independently, a hydrogen atom, a halo atom, a trifluoromethyl group, a C₁₋₄ alkyl group, a methylenedioxy group, a phenoxy group optionally substituted by a C₁₋₄ alkoxy group or by a halo atom; a C₂₋₄ alkenyl group, a C₂₋₄ alkenyloxy group, a C₁₋₄ alkoxy group optionally substituted by a di(C₁₋₄ alkyl)amino group or by a 5- or 6-membered, saturated heterocyclic group containing one or two nitrogen atom(s) or a nitrogen atom and an oxygen atom, wherein said heterocyclic group is optionally substituted by a C₁₋₄ alkyl group, or

A stands for a group of the formula

N-(CH₂)_n-Ar', wherein

Ar' represents a diphenylmethyl group, a pyridyl group, a pyrimidinyl group, a naphthyl group, wherein said latter group is optionally substituted by a C₁₋₄ alkoxy group or a C₂₋₄ alkenyloxy group; a partially saturated, 5- or 6-membered heterocyclic group condensed with a phenyl group and containing one or two oxygen atom(s), said heterocyclic group being optionally substituted by one to three C₁₋₄ alkyl

-139-

group(s); or a phenyl group substituted by the substituents R⁵, R⁶ and R⁷, wherein R⁵, R⁶ and R⁷ are as defined above,

n has a value of 0 or 1, or a pharmaceutically suitable acid addition salt thereof as the active ingredient and one or more conventional carrier(s).

9. A pharmaceutical composition as claimed in Claim 8, comprising a benzofuran derivative of the formula I, wherein

R¹ represents a hydrogen atom or a C₁₋₄ alkyl group,

R² stands for a hydrogen atom,

X means an oxygen atom,

Y is a hydrogen atom or a hydroxy group,

Z represents a hydrogen atom, a halo atom or a nitro group,

A stands for a group of the formula CH, COH or C-CN,

B means a methylene group, or

A forms with B a group of the formula -C=C-,

Ar represents a hydrogen atom, a benzyl group, a phenyl group substituted by substituents R⁵, R⁶ and R⁷, a biphenylyl group, a naphthyl group optionally substituted by a C₁₋₄ alkoxy group; or a thieryl group, wherein


R⁵, R⁶ and R⁷ mean, independently, a hydrogen atom, a halo atom, a trifluoromethyl group, a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a C₂₋₄ alkenyloxy

-140-

group, a phenoxy group or a methylenedioxy group, or a pharmaceutically suitable acid addition salt thereof as the active ingredient.

10. A pharmaceutical composition as claimed in Claim 8 or 9, comprising a benzofuran derivative of the formula I, wherein R¹ represents a methyl group, R² stands for a hydrogen atom, X means an oxygen atom, Y is a hydroxy group, Z represents a hydrogen atom, A is a group of the formula CH, COH or C-CN, B stands for a methylene group, or A forms with B a group of the formula -C=C-, Ar represents a phenyl group optionally substituted by a halo atom, a trifluoromethyl group, a methyl group or a methoxy group; or a methoxynaphthyl group, or a pharmaceutically suitable acid addition salt thereof as the active ingredient.

11. A pharmaceutical composition as claimed in Claim 8, comprising a piperazinyl-alkylbenzofuran derivative of the formula



wherein

-141-

R^1 represents a C_{1-4} alkyl group,
 R^2 stands for a hydrogen atom,
X means an oxygen atom,
Y is a hydroxy group,
Z represents a hydrogen atom,
 Ar' represents a diphenylmethyl group, a pyridyl group, a partially saturated 5-membered heterocyclic group containing two oxygen atoms and being condensed with a phenyl group, or a phenyl group substituted by substituents R^5 , R^6 and R^7 , wherein R^5 , R^6 and R^7 mean, independently, a hydrogen atom, a halo atom, a trifluoromethyl group, a C_{1-4} alkyl group, a C_{1-4} alkoxy group, or a methylenedioxy group,
n has a value of 0 or 1,
or a pharmaceutically suitable acid addition salt thereof as the active ingredient.

12. A pharmaceutical composition as claimed in Claim 11, comprising a piperazinyl-alkylbenzofuran derivative of the formula Ia, wherein
 R^1 represents a methyl group,
 R^2 stands for a hydrogen atom,
X means an oxygen atom,
Y is a hydroxy group,
Z represents a hydrogen atom,
 Ar' represents a diphenylmethyl group, a pyridyl group, a benzo-1,3-dioxolanyl group or a phenyl group optionally substituted

-142-

by one or two halo atom(s), one or two methyl group(s), a methylenedioxy group, a trifluoromethyl group or a methoxy group, n has a value of 0 or 1, or a pharmaceutically suitable acid addition salt thereof as the active ingredient.

13. A pharmaceutical composition as claimed in Claim 8, comprising one of the following compounds:

1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-(3-trifluoromethylphenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-(4-fluorophenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-phenylpiperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-(3-chlorophenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-(3-methoxyphenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-hydroxy-4-(4-methoxyphenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)-2-hydroxypropyl/-4-(3-trifluoromethyl-


-143-

phenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(4-methyl-phenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-cyano-4-phenyl-piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(4-chloro-phenyl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(6-methoxy-naphth-2-yl)piperidine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(diphenylmethyl)-piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(4-fluorophenyl)-piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-hydroxy-4-(3-trifluoro-methylphenyl)piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(4-methoxyphenyl)-piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(benzo-1,3-dioxolan-5-yl)piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(4-chlorophenyl)-piperazine,
1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-

-144-

oxy)-2-hydroxypropyl/-4-benzylpiperazine,
 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(2,4-dichlorophenyl)-piperazine,
 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(3-chlorophenyl)-piperazine,
 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(2-pyridyl)piperazine,
 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(2-methoxyphenyl)-piperazine or
 1-/3-(2,2-dimethyl-2,3-dihydro-benzofuran-7-yl-oxy)-2-hydroxypropyl/-4-(3-methoxyphenyl)-piperazine,
 or a pharmaceutically suitable acid addition salt thereof as the active ingredient.

14. A method of treatment in which a patient suffering especially from a heart disease or a disease of the central nervous system is treated with a non-toxic dose of a benzofuran derivative of the formula



wherein

R^1 and R^2 represent, independently, a hydrogen atom or a C₁₋₄ alkyl group,

-145-

X stands for an oxygen atom or a sulfur atom,
Y means a hydrogen atom or a hydroxy group,
Z represents a hydrogen atom, a halo atom,
a C₁₋₄ alkyl group, a C₁₋₄ alkoxy group,
an amino group, a nitro group, a cyano
group, a trifluoromethyl group, a group
of the formula -COOR³, -NHCOR³ or
-SO₂NR³R⁴, wherein
R³ stands for a hydrogen atom or a C₁₋₄
alkyl group,
R⁴ is a C₁₋₄ alkyl group, or
R³ and R⁴ form, together with the adjacent
nitrogen atom, a saturated or unsaturated
heterocyclic group having 5 to 10 members
and optionally comprising one or more
nitrogen atom(s) and/or one or more
oxygen atom(s) and/or one or more sulfur
atom(s) as the further heteroatom(s),
A means a group of the formula CH, COH, C-CN,
C-COOR³ or COR⁴, wherein R³ and R⁴ are
as defined above,
B represents a methylene group, or
A forms together with B a group of the formula
-C=C-,
Ar stands for a hydrogen atom, a C₁₋₄ alkyl
group, a phenyl(C₁₋₄ alkyl) group, a
biphenylyl group, a naphthyl group, wherein
said latter species are optionally
substituted by a C₁₋₄ alkoxy group or
a C₂₋₄ alkenyl group; a partially saturated,
5- or 6-membered heterocyclic group
condensed with a phenyl group and containing

-146-

one or two oxygen atom(s), said heterocyclic group being optionally substituted by one to three C₁₋₄ alkyl group; a 5- or 6-membered, saturated or unsaturated heterocyclic group containing a nitrogen atom and/or an oxygen atom and/or a sulfur atom as the heteroatom; or a phenyl group substituted by the substituents R⁵, R⁶ and R⁷, wherein R⁵, R⁶ and R⁷ mean, independently, a hydrogen atom, a halo atom, a trifluoromethyl group, a C₁₋₄ alkyl group, a methylenedioxy group, a phenoxy group optionally substituted by a C₁₋₄ alkoxy group or by a halo atom; a C₂₋₄ alkenyl group, a C₂₋₄ alkenyloxy group, a C₁₋₄ alkoxy group optionally substituted by a di(C₁₋₄ alkyl)amino group or by a 5- or 6-membered, saturated heterocyclic group containing one or two nitrogen atom(s) or a nitrogen atom and an oxygen atom, wherein said heterocyclic group is optionally substituted by a C₁₋₄ alkyl group, or

A stands for a group of the formula

N-(CH₂)_n-Ar', wherein


Ar' represents a diphenylmethyl group, a pyridyl group, a pyrimidinyl group, a naphthyl group, wherein said latter group is optionally substituted by a C₁₋₄ alkoxy group or a C₂₋₄ alkenyloxy group; a partially saturated, 5- or

-147-

6-membered heterocyclic group condensed with a phenyl group and containing one or two oxygen atom(s), said heterocyclic group being optionally substituted by one to three C_{1-4} alkyl group(s); or a phenyl group substituted by the substituents R^5 , R^6 and R^7 , wherein R^5 , R^6 and R^7 are as defined above,

n has a value of 0 or 1, or a pharmaceutically suitable acid addition salt thereof.

15. A process for the preparation of a pharmaceutical composition having especially cardioprotective action or being suitable for the treatment of a disease of the central nervous system, characterized in that a benzofuran derivative of the formula



wherein

R^1 and R^2 represent, independently, a hydrogen atom or a C_{1-4} alkyl group,

X stands for an oxygen atom or a sulfur atom,

Y means a hydrogen atom or a hydroxy group,

Z represents a hydrogen atom, a halo atom,

a C_{1-4} alkyl group, a C_{1-4} alkoxy group,

-148-

an amino group, a nitro group, a cyano group, a trifluoromethyl group, a group of the formula $-COOR^3$, $-NHCOR^3$ or $-SO_2NR^3R^4$, wherein

R^3 stands for a hydrogen atom or a C_{1-4} alkyl group,

R^4 is a C_{1-4} alkyl group, or

R^3 and R^4 form, together with the adjacent nitrogen atom, a saturated or unsaturated heterocyclic group having 5 to 10 members and optionally comprising one or more nitrogen atom(s) and/or one or more oxygen atom(s) and/or one or more sulfur atom(s) as the further heteroatom(s),

A means a group of the formula CH , COH , $C-CN$, $C-COOR^3$ or COR^4 , wherein R^3 and R^4 are as defined above,

B represents a methylene group, or

A forms together with B a group of the formula $-C=C-$,

Ar stands for a hydrogen atom, a C_{1-4} alkyl group, a phenyl(C_{1-4} alkyl) group, a biphenylyl group, a naphthyl group, wherein said latter species are optionally substituted by a C_{1-4} alkoxy group or a C_{2-4} alkenyl group; a partially saturated, 5- or 6-membered heterocyclic group condensed with a phenyl group and containing one or two oxygen atom(s), said heterocyclic group being optionally substituted by one to three C_{1-4} alkyl group; a 5- or 6-membered, saturated or unsaturated hetero

-149-

cyclic group containing a nitrogen atom and/or an oxygen atom and/or a sulfur atom as the heteroatom; or a phenyl group substituted by the substituents R^5 , R^6 and R^7 , wherein R^5 , R^6 and R^7 mean, independently, a hydrogen atom, a halo atom, a trifluoromethyl group, a C_{1-4} alkyl group, a methylenedioxy group, a phenoxy group optionally substituted by a C_{1-4} alkoxy group or by a halo atom; a C_{2-4} alkenyl group, a C_{2-4} alkenyloxy group, a C_{1-4} alkoxy group optionally substituted by a di(C_{1-4} alkyl)amino group or by a 5- or 6-membered, saturated heterocyclic group containing one or two nitrogen atom(s) or a nitrogen atom and an oxygen atom, wherein said heterocyclic group is optionally substituted by a C_{1-4} alkyl group, or

A stands for a group of the formula

$N-(CH_2)_n-Ar'$, wherein


Ar' represents a diphenylmethyl group, a pyridyl group, a pyrimidinyl group, a naphthyl group, wherein said latter group is optionally substituted by a C_{1-4} alkoxy group or a C_{2-4} alkenyloxy group; a partially saturated, 5- or 6-membered heterocyclic group condensed with a phenyl group and containing one or two oxygen atom(s), said heterocyclic group being optionally

-150-

substituted by one to three C_{1-4} alkyl group(s); or a phenyl group substituted by the substituents R^5 , R^6 and R^7 , wherein R^5 , R^6 and R^7 are as defined above,

n has a value of 0 or 1, or a pharmaceutically suitable acid addition salt thereof is converted to a pharmaceutical composition using one or more carrier(s) commonly employed in the manufacture of drugs.

16. A halide of the formula



wherein

R^1 and R^2 represents, independently, a hydrogen atom or a C_{1-4} alkyl group,

X stands for an oxygen atom or a sulfur atom,

Y means a hydrogen atom or a hydroxy group,

Z represents a hydrogen atom, a halo atom,

a C_{1-4} alkyl group, a C_{1-4} alkoxy group,

an amino group, a nitro group, a cyano

group, a trifluoromethyl group or a group

of the formula $-COOR^3$, $-NHCOR^3$ or $-SO_2NR^3R^4$,

wherein

R^3 stands for a hydrogen atom or a C_{1-4} alkyl group,


R^4 means a C_{1-4} alkyl group, or

-151-

R^3 and R^4 form, together with the adjacent nitrogen atom, a saturated or unsaturated heterocyclic group having 5 to 10 members and optionally comprising one or more nitrogen atom(s) and/or one or more oxygen atom(s) and/or one or more sulfur atom(s),

Hal represents a halo atom.

17. A ketone of the formula



XV

wherein

R^1 and R^2 represents, independently, a hydrogen atom or a C_{1-4} alkyl group,

X stands for an oxygen atom or a sulfur atom,

Y means a hydrogen atom or a hydroxy group,

Z represents a hydrogen atom, a halo atom,

a C_{1-4} alkyl group, a C_{1-4} alkoxy group,

an amino group, a nitro group, a cyano

group, a trifluoromethyl group or a group

of the formula $-COOR^3$, $-NHCOR^3$ or $-SO_2NR^3R^4$.

wherein

R^3 stands for a hydrogen atom or a C_{1-4} alkyl group,

R^4 means a C_{1-4} alkyl group, or

R^3 and R^4 form, together with the adjacent nitrogen atom, a saturated or unsaturated

-152-

heterocyclic group having 5 to 10 members and optionally comprising one or more nitrogen atom(s) and/or one or more oxygen atom(s) and/or one or more sulfur atom(s).